Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 12;10(1):ofac693. doi: 10.1093/ofid/ofac693

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Risk of respiratory syncytial virus (RSV) disease (defined by endpoint 2) in vaccine arm subgroups defined by antibody marker exceeding thresholds with antibody marker defined by fold-change (day 14/day 0 [D0]) in enzyme immunoassay (EIA) (A), palivizumab-competitive antibody (PCA) (B), RSV-A (C), or RSV-B (D); fold-change (infant cord blood [Cord]/D0) in EIA (E), PCA (F), RSV-A (G), or RSV-A (H); or Cord levels of EIA (I), PCA (J), RSV-A (K), or RSV-B (L), with adjustment for covariates. The Cord/D0 fold-change analyses were post hoc. The gray-shaded region indicates pointwise 95% confidence intervals and the green shaded region is the area under the reverse cumulative distribution function. The vertical dashed red line marks the threshold of estimated zero risk. Endpoint 2 was defined as RSV-associated lower respiratory tract infection with severe hypoxemia (14 vaccine endpoints). Abbreviations: CDF, cumulative distribution function; Cord, infant cord blood; D0, day 0; D14, day 14; EIA, enzyme immunoassay; OD, optical density; PCA, palivizumab-competitive antibody; RSV-A, respiratory syncytial virus subtype A; RSV-B, respiratory syncytial virus subtype B.